Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRIM-DJ2727 in Recurrent C. Difficile Infection
NCT03298048Phase 2Terminated
- Sponsor
- UTHealth Houston
- Start
- Dec 2017
- Primary completion
- Mar 2019
- Modality
- Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of PRIM-DJ2727 in Clostridium difficile infection (CDI) (3 arms), sponsored by UTHealth Houston. Primary endpoints: Number of Participants With Nausea at 180 days, Number of Participants With Vomiting at 180 days and 3 more. Started Dec 2017; status: terminated.
02
Drugs
PRIM-DJ2727
03
Conditions
Clostridium difficile infection (CDI)
Beyond the preview
Go deeper on NCT03298048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03298048.